What happened with LSTA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Lisata Therapeutics is a clinical-stage drug developer focused on certepetide, which is intended to be given alongside anti-cancer drugs to help more of those drugs enter and spread through solid tumors. Certepetide is the core of its CendR Platform, for which Lisata plans to pursue development partnerships. Its business depends heavily on this investigational treatment.
Lisata has no approved product and has never earned revenue from drug sales. Its limited revenue comes from licensing and collaboration agreements, including upfront license fees; these arrangements have included an Exclusive License and Collaboration Agreement with Kuva Labs. Future drug sales would require regulatory approval and would depend partly on government healthcare programs and private insurers covering and paying for treatment.
The company needs additional funding to continue operations and development. It also relies on outside manufacturers to supply its clinical trials and any future commercial production, with manufacturing required to meet regulatory standards.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Lisata’s prospects depend chiefly on certepetide’s clinical results and development funding; Kuva Labs is the collaboration to watch within its limited licensing revenue.
Processa Pharmaceuticals, Inc. Common offers an alternative to Lisata’s effort to help cancer drugs penetrate tumors: it modifies established cancer drugs to increase cancer-cell exposure while reducing toxicity. With no current contracted revenue or immediate sales prospects, Processa’s key test is whether its trials show better efficacy and tolerability than existing drugs.
Pliant Therapeutics, Inc. overlaps with Lisata in seeking better solid-tumor treatment through drugs that act on integrins, but Pliant blocks these proteins while Lisata’s certepetide binds them to help other cancer drugs enter tumors. Watch Pliant’s PLN-101095 results in solid tumors resistant to immune checkpoint inhibitors—the patient group its treatment targets.
Lisata Therapeutics, Inc. earningsThis company
Lisata Therapeutics is spending to develop its investigational drug, and this report will show whether its cash use leaves it needing funding sooner or gives it more room to continue.
Read cash used in operations alongside cash, cash equivalents and marketable securities. Lower cash use with the available balance holding up would mean more room to keep developing certepetide; higher cash use with a falling balance would mean greater dependence on financing or other funding, and possible pressure to change plans.
Pliant Therapeutics, Inc. earningsPLRX
Pliant Therapeutics’ report may show how its integrin-targeting drug is progressing in solid tumors, offering a read on a treatment approach that overlaps with Lisata’s effort to help cancer drugs reach tumors.
Look for Pliant’s clinical update on PLN-101095 in solid tumors resistant to immune checkpoint inhibitors. Clear progress would keep integrin-related treatment relevant in this patient group, but would not prove Lisata’s certepetide works; limited or inconclusive findings would leave that competitive signal unconfirmed.
